← Leaderboards
John D Minna
University Of Texas Sw Med Ctr/Dallas
$17,722,080
Attributed
$26,383,418
Total exposure
20
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$83,751,715 · 21
By mechanism
P50$67,192,449 · 14
U24$6,056,429 · 1
U01$5,807,571 · 2
R01$4,432,103 · 2
P30$243,163 · 1
R13$20,000 · 1
Top collaborators
- John B Macmillan9 shared
- Jack Roth9 shared
- John V. Heymach7 shared
- Bruce Arthur Posner5 shared
- Lauren Averett Byers4 shared
- Trudy Gale Oliver4 shared
- Michael G Roth4 shared
- Charles M Rudin4 shared
Most similar at University Of Texas Sw Med Ctr/Dallas
Same institution · by research overlap
- Gail Elizabeth Tomlinson$1,127,078
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungResearch PersonnelTumorUniversity Of Texas M D Anderson Cancer CenterCollaborationsUniversitiesLung NeoplasmsTexasBaseBioinformaticsPre-Clinical ModelResourcesCell LineBiometryMolecularAdvocateNon-Small-Cell Lung CarcinomaProgramsGrantInstitutionCancer TherapyResponsePre-ClinicalClinical Trials
Grant awards (137)
Coordinating center for the NCI small cell lung cancer research consortium$1,379,839
U24 · FY2025 · CA
Experimental Therapeutics Program$243,163
P30 · FY2025 · CA · contact PI
Targeting Lung Cancer Vulnerabilities$2,188,505
P50 · FY2024 · CA · contact PI
Coordinating center for the NCI small cell lung cancer research consortium$1,456,493
U24 · FY2024 · CA
Administrative Core A$179,698
P50 · FY2024 · CA · contact PI
Targeting Lung Cancer Vulnerabilities$2,110,656
P50 · FY2023 · CA · contact PI
Coordinating center for the NCI small cell lung cancer research consortium$1,565,497
U24 · FY2023 · CA
Project 3: Targeting Vulnerabilities in the Fibrotic Extracellular Matrix (ECM) of Lung Cancers$282,687
P50 · FY2023 · CA · contact PI
Administrative Core A$171,471
P50 · FY2023 · CA · contact PI
Targeting Lung Cancer Vulnerabilities$118,034
P50 · FY2023 · CA · contact PI
Targeting Lung Cancer Vulnerabilities$45,613
P50 · FY2023 · CA · contact PI
Targeting Lung Cancer Vulnerabilities$2,120,114
P50 · FY2022 · CA · contact PI
Coordinating center for the NCI small cell lung cancer research consortium$1,654,600
U24 · FY2022 · CA
Natural Products with Selective Cytoxicity to Non Small Cell Lung Cancer$596,434
R01 · FY2022 · CA · contact PI
Project 3: Targeting Vulnerabilities in the Fibrotic Extracellular Matrix (ECM) of Lung Cancers$282,686
P50 · FY2022 · CA · contact PI
Administrative Core A$171,472
P50 · FY2022 · CA · contact PI
Targeting Lung Cancer Vulnerabilities$2,125,682
P50 · FY2021 · CA · contact PI
Natural Products with Selective Cytoxicity to Non Small Cell Lung Cancer$608,607
R01 · FY2021 · CA · contact PI
Developing ASCL1 and NeuroD1 lineage oncogene targeted therapy for small cell lung cancer$605,070
U01 · FY2021 · CA · contact PI
Project 3: Targeting Vulnerabilities in the Fibrotic Extracellular Matrix (ECM) of Lung Cancers$238,661
P50 · FY2021 · CA · contact PI
Administrative Core A$174,081
P50 · FY2021 · CA · contact PI
Targeting Lung Cancer Vulnerabilities$2,203,273
P50 · FY2020 · CA · contact PI
Natural Products with Selective Cytoxicity to Non Small Cell Lung Cancer$608,607
R01 · FY2020 · CA · contact PI
Developing ASCL1 and NeuroD1 lineage oncogene targeted therapy for small cell lung cancer$605,070
U01 · FY2020 · CA · contact PI
Project 3: Targeting Vulnerabilities in the Fibrotic Extracellular Matrix (ECM) of Lung Cancers$260,117
P50 · FY2020 · CA · contact PI
Administrative Core A$194,633
P50 · FY2020 · CA · contact PI
SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer$1,109,454
P50 · FY2019 · CA · contact PI
Natural Products with Selective Cytoxicity to Non Small Cell Lung Cancer$590,349
R01 · FY2019 · CA · contact PI
Developing ASCL1 and NeuroD1 lineage oncogene targeted therapy for small cell lung cancer$586,917
U01 · FY2019 · CA · contact PI
SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer$2,299,999
P50 · FY2018 · CA · contact PI
Natural Products with Selective Cytoxicity to Non Small Cell Lung Cancer$624,106
R01 · FY2018 · CA · contact PI
Developing ASCL1 and NeuroD1 lineage oncogene targeted therapy for small cell lung cancer$605,070
U01 · FY2018 · CA · contact PI
Molecular Signatures for Individualizing Lung Cancer Therapy$418,550
P50 · FY2018 · CA · contact PI
Administrative Core$204,191
P50 · FY2018 · CA · contact PI
Career Development Program$80,751
P50 · FY2018 · CA · contact PI
Developmental Research Program$80,751
P50 · FY2018 · CA · contact PI
SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer$2,299,998
P50 · FY2017 · CA · contact PI
Developing ASCL1 and NeuroD1 lineage oncogene targeted therapy for small cell lung cancer$605,070
U01 · FY2017 · CA · contact PI
Molecular Signatures for Individualizing Lung Cancer Therapy$418,554
P50 · FY2017 · CA · contact PI
Administrative Core$204,191
P50 · FY2017 · CA · contact PI
Career Development Program$80,749
P50 · FY2017 · CA · contact PI
Developmental Research Program$80,749
P50 · FY2017 · CA · contact PI
SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer$2,162,000
P50 · FY2016 · CA · contact PI
SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer$750,052
P50 · FY2016 · CA · contact PI
Lung cancer oncogenotype-selective drug target discovery$706,409
U01 · FY2016 · CA
Molecular Signatures for Individualizing Lung Cancer Therapy$393,439
P50 · FY2016 · CA · contact PI
Administrative Core$191,940
P50 · FY2016 · CA · contact PI
Career Development Program$75,904
P50 · FY2016 · CA · contact PI
Developmental Research Program$75,904
P50 · FY2016 · CA · contact PI
SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer$2,041,142
P50 · FY2015 · CA · contact PI
Lung cancer oncogenotype-selective drug target discovery$706,409
U01 · FY2015 · CA
Molecular Signatures for Individualizing Lung Cancer Therapy$371,821
P50 · FY2015 · CA · contact PI
Administrative Core$179,309
P50 · FY2015 · CA · contact PI
Career Development Program$71,738
P50 · FY2015 · CA · contact PI
Developmental Research Program$71,738
P50 · FY2015 · CA · contact PI
SPORE: Developing New Rationale, Personalized Medicine for Lung Cancer$2,161,999
P50 · FY2014 · CA · contact PI
Lung cancer oncogenotype-selective drug target discovery$685,218
U01 · FY2014 · CA
Molecular Signatures for Individualizing Lung Cancer Therapy$397,276
P50 · FY2014 · CA · contact PI
Administrative Core$173,223
P50 · FY2014 · CA · contact PI
Career Development Program$76,649
P50 · FY2014 · CA · contact PI
Developmental Research Program$76,649
P50 · FY2014 · CA · contact PI
Lung cancer oncogenotype-selective drug target discovery$702,338
U01 · FY2013 · CA
University of Texas SPORE in Lung Cancer$560,104
P50 · FY2013 · CA · contact PI
P-1: Molecular Signatures for Individualizing Lung Cancer Therapy$156,620
P50 · FY2013 · CA · contact PI
CA: Administration Core$75,485
P50 · FY2013 · CA · contact PI
University of Texas SPORE in Lung Cancer$2,300,000
P50 · FY2012 · CA · contact PI
P-1: Molecular Signatures for Individualizing Lung Cancer Therapy$261,985
P50 · FY2012 · CA · contact PI
CA: Administration Core$216,355
P50 · FY2012 · CA · contact PI
University of Texas SPORE in Lung Cancer$2,185,000
P50 · FY2011 · CA · contact PI
P-1: Molecular Signatures for Individualizing Lung Cancer Therapy$248,398
P50 · FY2011 · CA · contact PI
CA: Administration Core$206,797
P50 · FY2011 · CA · contact PI
University of Texas SPORE in Lung Cancer$2,300,000
P50 · FY2010 · CA · contact PI
P-1: Molecular Signatures for Individualizing Lung Cancer Therapy$261,165
P50 · FY2010 · CA · contact PI
CA: Administration Core$219,213
P50 · FY2010 · CA · contact PI
University of Texas SPORE in Lung Cancer$2,300,000
P50 · FY2009 · CA · contact PI
P-1: Molecular Signatures for Individualizing Lung Cancer Therapy$260,955
P50 · FY2009 · CA · contact PI
CA: Administration Core$220,871
P50 · FY2009 · CA · contact PI
University of Texas SPORE in Lung Cancer$2,300,000
P50 · FY2008 · CA · contact PI
P-1: Molecular Signatures for Individualizing Lung Cancer Therapy$217,117
P50 · FY2008 · CA · contact PI
CA: Administration Core$183,259
P50 · FY2008 · CA · contact PI
SPORE in Lung Cancer$2,353,640
P50 · FY2007 · CA · contact PI
Translation of tumor suppressor genes into new lung cancer therapeutics$308,700
P50 · FY2007 · CA · contact PI
DEVELOPMENTAL RESEARCH PROGRAM$188,250
P50 · FY2007 · CA · contact PI
SPORE in Lung Cancer$2,423,934
P50 · FY2006 · CA · contact PI
Translation of tumor suppressor genes to lung cancer the$308,700
P50 · FY2006 · CA · contact PI
DEVELOPMENTAL RESEARCH PROGRAM$188,250
P50 · FY2006 · CA · contact PI
SPORE in Lung Cancer$16,676
P50 · FY2006 · CA · contact PI
SPORE in Lung Cancer$2,599,687
P50 · FY2005 · CA
SPORE in Lung Cancer$71,760
P50 · FY2005 · CA
Molecular Pathology of Lung Cancer$20,000
R13 · FY2005 · CA
SPORE in Lung Cancer$2,487,605
P50 · FY2004 · CA
Characterization of Human 3p Recessive Oncogenes$351,000
R01 · FY2004 · CA
SPORE in Lung Cancer$71,760
P50 · FY2004 · CA
SPORE in Lung Cancer$2,500,000
P50 · FY2003 · CA
Characterization of Human 3p Recessive Oncogenes$351,000
R01 · FY2003 · CA
UNIVERSITY OF TEXAS SPORE IN LUNG CANCER$2,736,355
P50 · FY2002 · CA
Characterization of Human 3p Recessive Oncogenes$351,000
R01 · FY2002 · CA
UNIVERSITY OF TEXAS SPORE IN LUNG CANCER$77,250
P50 · FY2002 · CA
CAREER DEVELOPMENT PROGRAM$0
P50 · FY2002 · CA
DEVELOPMENTAL RESEARCH PROGRAM$0
P50 · FY2002 · CA
CAREER DEVELOPMENT PROGRAM$0
P50 · FY2002 · CA
IDENTIFICATION OF 3P RECESSIVE ONCOGENES IN LUNG CANCER$0
P50 · FY2002 · CA
IDENTIFICATION OF 3P RECESSIVE ONCOGENES IN LUNG CANCER$0
P50 · FY2002 · CA
DEVELOPMENTAL RESEARCH PROGRAM$0
P50 · FY2002 · CA
UNIVERSITY OF TEXAS SPORE IN LUNG CANCER$2,497,516
P50 · FY2001 · CA
Characterization of Human 3p Recessive Oncogenes$351,000
R01 · FY2001 · CA
UNIVERSITY OF TEXAS SPORE IN LUNG CANCER$212,382
P50 · FY2001 · CA
UNIVERSITY OF TEXAS SPORE IN LUNG CANCER$80,340
P50 · FY2001 · CA
CAREER DEVELOPMENT PROGRAM$0
P50 · FY2001 · CA
DEVELOPMENTAL RESEARCH PROGRAM$0
P50 · FY2001 · CA
DEVELOPMENTAL RESEARCH PROGRAM$0
P50 · FY2001 · CA
DEVELOPMENTAL RESEARCH PROGRAM$0
P50 · FY2001 · CA
IDENTIFICATION OF 3P RECESSIVE ONCOGENES IN LUNG CANCER$0
P50 · FY2001 · CA
IDENTIFICATION OF 3P RECESSIVE ONCOGENES IN LUNG CANCER$0
P50 · FY2001 · CA
IDENTIFICATION OF 3P RECESSIVE ONCOGENES IN LUNG CANCER$0
P50 · FY2001 · CA
CAREER DEVELOPMENT PROGRAM$0
P50 · FY2001 · CA
CAREER DEVELOPMENT PROGRAM$0
P50 · FY2001 · CA
UNIVERSITY OF TEXAS SPORE IN LUNG CANCER$2,224,767
P50 · FY2000 · CA
UNIVERSITY OF TEXAS SPORE IN LUNG CANCER$980,000
P50 · FY2000 · CA
IDENTIFICATION OF 3P RECESSIVE ONCOGENES IN LUNG CANCER$308,700
P50 · FY2000 · CA
UNIVERSITY OF TEXAS SPORE IN LUNG CANCER$200,000
P50 · FY2000 · CA
DEVELOPMENTAL RESEARCH PROGRAM$188,250
P50 · FY2000 · CA
CAREER DEVELOPMENT PROGRAM$125,500
P50 · FY2000 · CA
UNIVERSITY OF TEXAS SPORE IN LUNG CANCER$78,000
P50 · FY2000 · CA
UNIVERSITY OF TEXAS SPORE IN LUNG CANCER$75,000
P50 · FY2000 · CA
DEVELOPMENTAL RESEARCH PROGRAM$0
P50 · FY2000 · CA
DEVELOPMENTAL RESEARCH PROGRAM$0
P50 · FY2000 · CA
DEVELOPMENTAL RESEARCH PROGRAM$0
P50 · FY2000 · CA
IDENTIFICATION OF 3P RECESSIVE ONCOGENES IN LUNG CANCER$0
P50 · FY2000 · CA
IDENTIFICATION OF 3P RECESSIVE ONCOGENES IN LUNG CANCER$0
P50 · FY2000 · CA
CAREER DEVELOPMENT PROGRAM$0
P50 · FY2000 · CA
IDENTIFICATION OF 3P RECESSIVE ONCOGENES IN LUNG CANCER$0
P50 · FY2000 · CA
CAREER DEVELOPMENT PROGRAM$0
P50 · FY2000 · CA
CAREER DEVELOPMENT PROGRAM$0
P50 · FY2000 · CA
CAREER DEVELOPMENT PROGRAM$0
P50 · FY2000 · CA
IDENTIFICATION OF 3P RECESSIVE ONCOGENES IN LUNG CANCER$0
P50 · FY2000 · CA
DEVELOPMENTAL RESEARCH PROGRAM$0
P50 · FY2000 · CA